Information Provided By:
Fly News Breaks for August 13, 2019
AMGN, NVS
Aug 13, 2019 | 07:23 EDT
Oppenheimer analyst Jay Olson raised his price target for Amgen (AMGN) to $230 from $210 after the U.S. District Court determined that Sandoz has not met the burden to prove all seven asserted claims invalid and upheld several Enbrel patents. The analyst suspects Sandoz will appeal but views the outcome as highly favorable for Amgen and models flat Enbrel sales until 2021 before declining. Sandoz is a division of Novartis (NVS). Olson reiterates an Outperform rating on Amgen's shares.
News For AMGN;NVS From the Last 2 Days
NVS
Sep 19, 2019 | 13:05 EDT
In an exclusive interview with The Fly, Cryoport (CYRX) President and CEO Jerry Shelton talked about the company, recent partnerships, growth and expansion plans, and much more. Here are some... To see the rest of the story go to thefly.com. See Story Here
NVS
Sep 18, 2019 | 10:58 EDT
Sandoz's decision follows the recent news of U.S. and EU probes of carcinogens found in the drug.
NVS
Sep 17, 2019 | 08:16 EDT
Immutep Limited (IMMP) announced the grant of patent no. 6576962 entitled "Antibody molecules to LAG-3 and uses thereof" by the Japanese Patent Office.The claims of the patent are directed to LAG525, and to the use of LAG525 in the treatment of cancer and infectious disease. LAG525 is a humanised form of Immutep's IMP701 antibody that was originally developed by Immutep, a wholly owned subsidiary of the Company. The patent is co-owned by Novartis AG (NVS) and Immutep S.A.S. and will expire on 13 March 2035.